📖Peter Lynch
Stalwarts
Stalwarts are your portfolio insurance — they protect you in downturns and deliver steady 10-12% annual returns.
Stalwarts are large companies that grow faster than slow growers but aren't going to double overnight.
🏠 Everyday Analogy
📖 Core Interpretation
Large companies with annual growth rates of 10-12%, such as Coca-Cola and Procter & Gamble, provide protection during economic downturns.
💎 Key Insight:Companies like Coca-Cola and Procter & Gamble grow at 10-12% and rarely collapse. Lynch uses stalwarts as portfolio anchors during uncertain markets. The key is buying them at reasonable prices and knowing when to rotate out. You typically make 30-50% on a stalwart over two years, then move on to the next one. Never overpay for safety.
AI Deep Analysis
Get personalized insights and practical guidance through AI conversation
❓ Why It Matters
Providing moderate growth and downside protection serves as the ballast of the investment portfolio.
🎯 How to Practice
Focus on whether the price-to-earnings ratio is reasonable, and consider selling after holding for 2-4 years to achieve a 30-50% return.
🎙️ Master's Voice
There are six types of stocks: slow growers, stalwarts, fast growers, cyclicals, turnarounds, and asset plays.
Lynch categorized every stock by type. Each category required different analysis, expectations, and holding periods.
⚔️ Practical Guide
✅ Decision Checklist
- What type of stock is this?
- Am I applying the right framework?
- Are my expectations appropriate?
📋 Action Steps
- Categorize each investment
- Apply category-specific analysis
- Set appropriate expectations
🚨 Warning Signs
- No clear categorization
- Wrong expectations
- One-size-fits-all approach
⚠️ Common Pitfalls
Do not buy at excessively high prices.
Growth may decelerate as scale expands.
📚 Case Studies
1
Coca-Cola Global Expansion (1986)
Coca-Cola accelerated international growth and improved marketing efficiency, driving steady earnings gains and dividend increases.
✨ Outcome:Long-term holders saw substantial capital appreciation as the stock compounded steadily through the late 1980s and 1990s.
2
Bristol-Myers Drug Pipeline (1985)
Bristol-Myers benefited from a strong lineup of established drugs and new therapies, supporting reliable earnings and dividend growth.
✨ Outcome:Investors who held the stalwart enjoyed stable returns and lower volatility versus the broader market over many years.
📌 Save this principle as your rule
One click to drop it into your personal rule library — every future trade will be scored against it.
See how masters handle real scenarios?
30 real investment dilemmas answered by legendary investors
Explore Scenarios →